Financial Instruments Business Operator Kanto Finance Bureau Director (Kinsho) No. 1960 / Membership Association Japan Investment Advisers Association Membership No. 012-02323 Go to GogoJungle Home
icon List
Ken
04/04/2024 16:20
Release： 04/04/2024 16:20
Update： 04/04/2024 16:20
Single article
$0.63
Reference price (JPY): ￥100 (taxed)
icon
Series
Electric revolution: Tesla and AI that reads ahead, innovations in technology such as batteries?
This series focuses on Tesla, the pioneer of electric vehicles, delving into its latest news, stock price movements, and groundbreaking technological innovations. For investors, it offers opportunities to foresee next-generation trends and add value to portfolios, not just track information. Updated daily, this series captures market movements in real time and shares deep insights related to the future of not only Tesla but the entire electric vehicle industry. From the latest news about Tesla to industry‑changing new technologies and notable emerging companies, it is a must-read series for a comprehensive understanding of the electric vehicle sector.
$31.36/month
Reference price (JPY): ￥4,980/月 (taxed)
Monthly subscriptions are only available on the Japanese site.
Article cover image

Moderna's Revolution: mRNA Technology Is Transforming the Future of Medicine

Introduction

Moderna is a biotechnology company that holds the key to shaping the future of medicine. This will explore why the company has attracted attention and how it faced a global pandemic. The mRNA technology developed by Moderna holds the potential to fundamentally transform not only the fight against COVID-19 but future medical care.

Overview of Moderna

Company history and founding background

Founded in 2010, Moderna specializes in developing therapies using mRNA (messenger RNA) technology. The aim of mRNA technology is to deliver instructions directly to the body's cells to fight disease, enabling faster and more efficient treatments than traditional therapies.

Fundamental principles of mRNA technology

mRNA technology carries messages that prompt body cells to produce specific proteins. By leveraging this process, it can mimic the naturally occurring immune responses in the body and enhance protection or therapeutic effects against diseases.

×
View reviews
From here onward is paid content
Single article
Single subscription
$0.63
Reference price (JPY): ￥100 (taxed)
icon
Series
Serial subscription
$31.36/month
Reference price (JPY): ￥4,980/月 (taxed)
Monthly subscriptions are only available on the Japanese site.
icon-free-first-month
Popular articles in the series
Tesla's Strategic Shift: Plan to Halt Mass-Market Electric Vehicles and Focus on Autonomous Driving Robotic Taxis
IntroductionTesla has decided to suspend its previously proposed plan to manufacture a mass-market e
Moderna's Revolution: mRNA Technology Is Transforming the Future of Medicine
IntroductionModerna is a biotechnology company that holds the key to shaping the future of medicine.
Tesla's entry into India: Large-scale investment plans under the Modi administration
IntroductionIn recent years, news that the global electric vehicle (EV) manufacturer Tesla is planni
Tesla 2024 Q1 Review: Delivery figures below analyst expectations, but there is a glimmer of light for the future
IntroductionThe first quarter of 2024 was a period where Tesla faced many challenges and achievement
Tesla Sales Forecast for Q1 2024: Challenges and Opportunities in the EV Market
IntroductionIn 2023, Tesla ceded the title of the world's largest electric vehicle (EV) maker to BYD
See all
■ Important Matters and Risk Warnings Regarding Investment Products 【Financial Instruments Business Operator】
GogoJungle Inc.
Registration: Director-General of the Kanto Local Finance Bureau (Financial Instruments Business) No. 1960
【Member Association】
Japan Investment Advisers Association
【Fees and Expenses】
The use of software, e-books, investment advisory services, etc., provided on our platform involves purchase prices determined for each product.
Additionally, when conducting actual financial instrument transactions (such as FX or CFD trading), costs such as transaction fees and spreads (the difference between the sell and buy price) may be incurred through the connected brokerage firms.
【Margin and Risk of Loss】
Transactions such as FX (Foreign Exchange Margin Trading) and CFD (Contract for Difference) allow for trading in amounts exceeding the deposited margin.
Therefore, due to sudden fluctuations in target indices (currency, commodity prices, etc.), there is a risk of incurring losses that exceed the deposited margin (loss exceeding principal).
Furthermore, financial instrument transactions involve risks such as price fluctuations, which may result in losses falling below or exceeding the initial investment principal.
【Nature of Services and Trading Entity】
The Company operates a platform (marketplace) providing investment software and information; we do not engage in the buying, selling, mediation, brokerage, or agency of financial instruments on behalf of customers.
The services and information provided are intended as reference for investment decisions and do not guarantee future profits or specific results.
While some services include investment advice, they do not constitute a mandate or solicitation to trade specific financial instruments.
Final investment decisions and the execution of trades must be made at the customer’s own risk and discretion.
GogoJungle Inc.
Registration: Director-General of the Kanto Local Finance Bureau (Financial Instruments Business) No. 1960
Member Association: Japan Investment Advisers Association GogoJungle Inc.
Registration: Director-General of the Kanto Local Finance Bureau (Financial Instruments Business) No. 1960
Member Association: Japan Investment Advisers Association
Financial Services Agency Japan Investment Advisers Association Financial Instruments Mediation Assistance Center Securities and Exchange Surveillance Commission

Copyright © 2026 GogoJungle Inc. All Rights Reserved.